Maidstone and Tunbridge Wells NHS Trust

Ref: FOI/GS/ID 4335

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net

30 November 2017

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Urothelial Cell Cancer.

1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust: All Urothelial cancer (UCC, transitional carcinoma, TCC) patients Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients 2. Of the metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies: Cisplatinum single agent Cisplatinum in combination with another agent Carboplatinum single agent Carboplatinum in combination with another agent Any other chemo regimen without cisplatinum or carboplatinum Pembrolizumab (Keytruda) Atezolizumab (Tecentriq) 3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:

1	
	•

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)	Number not treated
All Urothelial cancer (UCC,	205	30	2

transitional carcinoma, TCC) patients			
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients	5	1	0

2.

Therapy	Number of metastatic* or
	locally advanced* Urothelial
	-
	cancer (UCC, transitional
	carcinoma, TCC) patients
	currently treated
Cisplatinum single agent	
Cisplatinum in combination with another	1
agent	
Carboplatinum single agent	
Carboplatinum in combination with another	
agent	
agent	
Any other chemo regimen without	
cisplatinum or carboplatinum	
Pembrolizumab (Keytruda)	
Atezolizumab (Tecentriq)	
*TNINA stanta (second second s	

*TNM staging for metastatic Urothelial Cancer = Any T, any N, M1 *TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0